2月21日 - ** 药物开发商Acelyrin SLRN.O股价盘前上涨17.05%至2.54美元
** SLRN证实 (link)，投资者Tang Capital Partners的私人关联公司Concentra Biosciences提议以每股3美元的现金收购该公司，比上次收盘价高出38.2%。
** 根据路透社的计算，这一报价意味着约 3 亿美元的股权价值，外加 "或有价值权
** 该投资者持有 SLRN 5.3% 的股份--备案 (link)
** 本月早些时候，SLRN 宣布与 Alumis ALMS.O 达成协议， (link)，以全股票交易的方式合并。
** 自1月初报告其甲状腺眼病药物 (link) 的中期数据以来，SLRN的股价下跌了近38%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.